CDXS Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of --. Codexis, Inc.'s return on equity of -112.54% beat CEL-SCI Corp.'s return on equity of -266.61%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 259.75%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Codexis, Inc., analysts believe CEL-SCI Corp. is more attractive than Codexis, Inc..

Codexis, Inc. has a beta of 2.468, which suggesting that the stock is 146.83% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are larger than CEL-SCI Corp. quarterly revenues of --. Codexis, Inc.'s net income of -$19.6M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 2.93x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals, Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of -6183.44%. Codexis, Inc.'s return on equity of -112.54% beat EyePoint Pharmaceuticals, Inc.'s return on equity of -79.15%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 259.75%. On the other hand EyePoint Pharmaceuticals, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 100.11%. Given that Codexis, Inc. has higher upside potential than EyePoint Pharmaceuticals, Inc., analysts believe Codexis, Inc. is more attractive than EyePoint Pharmaceuticals, Inc..

Codexis, Inc. has a beta of 2.468, which suggesting that the stock is 146.83% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.808%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. EyePoint Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are larger than EyePoint Pharmaceuticals, Inc. quarterly revenues of $966K. Codexis, Inc.'s net income of -$19.6M is higher than EyePoint Pharmaceuticals, Inc.'s net income of -$59.7M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while EyePoint Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 2.93x versus 28.74x for EyePoint Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of 33.68%. Codexis, Inc.'s return on equity of -112.54% beat Merck & Co., Inc.'s return on equity of 39.63%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 259.75%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Codexis, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Codexis, Inc. is more attractive than Merck & Co., Inc..

Codexis, Inc. has a beta of 2.468, which suggesting that the stock is 146.83% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Codexis, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Codexis, Inc. quarterly revenues are $8.6M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Codexis, Inc.'s net income of -$19.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 2.93x versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tarsus Pharmaceuticals, Inc. has a net margin of -228.06% compared to Codexis, Inc.'s net margin of -10.6%. Codexis, Inc.'s return on equity of -112.54% beat Tarsus Pharmaceuticals, Inc.'s return on equity of -27.56%.

Codexis, Inc. has a consensus price target of $6.58, signalling upside risk potential of 259.75%. On the other hand Tarsus Pharmaceuticals, Inc. has an analysts' consensus of $86.11 which suggests that it could grow by 5.31%. Given that Codexis, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Codexis, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Codexis, Inc. has a beta of 2.468, which suggesting that the stock is 146.83% more volatile than S&P 500. In comparison Tarsus Pharmaceuticals, Inc. has a beta of 0.745, suggesting its less volatile than the S&P 500 by 25.508%.

Codexis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tarsus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis, Inc. pays -- of its earnings as a dividend. Tarsus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Codexis, Inc. quarterly revenues are $8.6M, which are smaller than Tarsus Pharmaceuticals, Inc. quarterly revenues of $118.7M. Codexis, Inc.'s net income of -$19.6M is lower than Tarsus Pharmaceuticals, Inc.'s net income of -$12.6M. Notably, Codexis, Inc.'s price-to-earnings ratio is -- while Tarsus Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis, Inc. is 2.93x versus 9.09x for Tarsus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.